Immunoreactive regions of glycoprotein gpII of varicella zoster virus (VZV)
View Patent ↗The present invention relates to immunoreactive peptides that are homologous with the region encompassing amino acid positions 450 to 655 of glycoprotein II of varicella zoster virus. In this context, preference is given to those peptides corresponding to segments of amino acids 505 to 647, 517 to 597, 535 to 584 or 545 to 582. The immunoreactive peptides are useful for methods of diagnosing varicella zoster virus infection.
1. A method for detecting antibodies against varicella zoster virus (VZV) in a sample suspected of containing antibodies to VZV, comprising the step of contacting an immunoreactive polypeptide of SEQ ID NO: 2 with the sample, wherein the immunoreactive polypeptide has an amino acid sequence that comprises the region encompassing AA450 to AA655 of gpII of VZV, and detecting bound antibody, wherein detected bound antibody indicates the presence of antibody in the sample.
2. A method for detecting antibodies against VZV in a sample suspected of containing antibodies to VZV, comprising the step of contacting an immunoreactive polypeptide of SEQ ID NO: 2 with the sample, wherein the immunoreactive polypeptide is encoded by a nucleic acid sequence of 618 bp or less that hybridizes under stringent conditions to a nucleic acid of SEQ ID NO: 1 and the polypeptide is recognized by antibodies that bind SEQ ID NO: 2; and detecting bound antibody, wherein the detection of bound antibody indicates the presence of antibody In the sample.
3. A method for detecting antibodies against Varicella Zoster virus (VZV) in a sample suspected of containing antibodies to VZV, comprising the steps of:
a) contacting an immunoreactive polypeptide comprising an amino acid sequence of SEQ ID NO: 2, wherein the polypeptide comprises a diagnostically utilizable epitope from the region encompassing amino acid positions 450 to 655 of glycoprotein gpII of VZV; and
b) detecting bound antibody, wherein the detection of bound antibody indicates the presence of antibody in the sample.
4. The method of claim 3 , wherein the immunoreactive polypeptide comprises a sequence selected from the group consisting of: AA 545 to 582 of glycoprotein gpII of varicella zoster virus (VZV), which correspond to AA 95 to 132 of SEQ ID NO:2; AA 535 to 584 of glycoprotein gpII of VZV, which correspond to AA 85 to 134 of SEQ ID NO:2; AA 517 to 597 of glycoprotein gpII of VZV, which correspond to AA 67 to 147 of SEQ ID NO:2; AA 505 to 647 of glycoprotein gpII of VZV, which correspond to AA 55 to 197 of SEQ ID NO:2; and an amino acid sequence that corresponds to the nucleotide sequence of SEQ ID NO: 1.
5. The method of claim 3 , wherein the sample is a blood sample, plasma sample or serum sample.